Molecular Partners AG ADR Cash Flow Conversion Efficiency
Molecular Partners AG ADR cash flow conversion efficiency. Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has a cash flow conversion efficiency ratio of -0.185x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.81 Million) by net assets ($58.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Molecular Partners AG ADR (2013–2025)
Cash flow conversion efficiency of Molecular Partners AG ADR from 2013 to 2025. This chart illustrates how Molecular Partners AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Molecular Partners AG ADR stock price today for real-time trading data and today's change.
Molecular Partners AG ADR Cash Flow Conversion Ratio Explained
Molecular Partners AG ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Molecular Partners AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Partners AG ADR ranked by their cash flow conversion efficiency. Also see MOLN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Saraswanti Anugerah Makmur Pt
JK:SAMF
|
0.243x |
|
Digital Aria Co Ltd
KQ:115450
|
-0.019x |
|
Digital Daesung Co. Ltd
KQ:068930
|
0.099x |
|
PTC India Financial Services Limited
NSE:PFS
|
0.379x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
Mieco Chipboard Bhd
KLSE:5001
|
0.023x |
|
Real Matters Inc
TO:REAL
|
-0.006x |
|
Renaissance Global Limited
NSE:RGL
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Molecular Partners AG ADR (2013–2025)
The table below shows the annual cash flow conversion efficiency of Molecular Partners AG ADR from 2013 to 2025. Review Molecular Partners AG ADR (MOLN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.33 Million | $-51.26 Million | -0.638x | -52.53% |
| 2024-12-31 | $141.64 Million | $-59.25 Million | -0.418x | -25.08% |
| 2023-12-31 | $176.43 Million | $-59.01 Million | -0.334x | -166.33% |
| 2022-12-31 | $235.17 Million | $118.57 Million | 0.504x | +159.47% |
| 2021-12-31 | $107.29 Million | $-90.95 Million | -0.848x | -213.61% |
| 2020-12-31 | $107.22 Million | $-28.98 Million | -0.270x | -1130.82% |
| 2019-12-31 | $54.14 Million | $-1.19 Million | -0.022x | +95.26% |
| 2018-12-31 | $91.70 Million | $-42.47 Million | -0.463x | -35.09% |
| 2017-12-31 | $116.73 Million | $-40.02 Million | -0.343x | -31.60% |
| 2016-12-31 | $135.79 Million | $-35.38 Million | -0.261x | -249.27% |
| 2015-12-31 | $151.79 Million | $26.50 Million | 0.175x | +328.68% |
| 2014-12-31 | $148.48 Million | $-11.33 Million | -0.076x | +72.91% |
| 2013-12-31 | $48.32 Million | $-13.61 Million | -0.282x | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more